IDEXX Laboratories revenue and financials

IDXX · NASDAQ · USD

$515.41−2.21%−$11.66

Close · October 6, 2026

In the fiscal year ended December 2025, IDEXX Laboratories reported revenue of $4.3B (+10.42% year over year). Net income was $1.06B, a net margin of 24.6%.

Annual revenue · 2025: $4.3B
  1. $1.78B2016
  2. $1.97B2017
  3. $2.21B2018
  4. $2.41B2019
  5. $2.71B2020
  6. $3.22B2021
  7. $3.37B2022
  8. $3.66B2023
  9. $3.9B2024
  10. $4.3B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+10.42%
2025 vs 2024
Net income growth
+19.33%
2025 vs 2024
Net margin
24.6%
2024: 22.8%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets3,4423,3853,3513,3873,3313,2143,2933,3513,4153,3543,2603,086
Current assets1,5091,4541,4141,4771,3621,3181,4001,4341,5291,5021,4951,384
Cash and equivalents197201180208165164288309402397454332
Receivables742697693715663604561587608578530522
Inventory392382378392393396382390380391380394
Net property, plant and equipment856862871868869834829839828829818805
Goodwill411412414414414407405412408409366362
Other intangible assets98.210511011510410711210711111584.587.1
Long-term investments28.827.631.831.831.031.031.030.030.030.030.330.3
Current liabilities1,2881,3001,1491,2521,2241,1361,0681,0091,117957952970
Accounts payable129130110122117120114111117117111113
Long-term debt300300375375450450450525525621623619
Total debt1,0961,1059761,1131,237———————
Total liabilities1,8301,8291,7451,8261,8721,7661,6981,7331,8351,7851,7751,789
Total equity (incl. minority)1,6131,5561,6051,5611,4591,4481,5951,6181,5801,5691,4851,297
Retained earnings7,0096,6706,3926,1445,8695,5755,3325,1164,8834,6804,4454,250